“Could be a comp plan they set in place for what
Post# of 148110
My problem with this is that NP’s forecasts are always very, very optimistic. He probably tells the board and his close friends how the PPS should be $49 right now and not $4.92 because of the multiple indications for leronlimab and all the tears shed over preclinical data. His beliefs about approvals and timeframes are not based on reality. If NP wants to award himself 1 million shares at the approval of leronlimab for COVID19, I’ll approve it, but not a moment earlier.